Abstract
Clinical trials of cholinesterase inhibitor (ChEI) drugs, although generally reporting only minimal improvements in patients with Alzheimers disease (AD), indicate that a subgroup of patients may respond substantially to treatment. This study aimed to assess the clinically variable ChEI treatment effects in a group of patients with mild AD using a semantic association and an N-back light working memory activation paradigm. Twenty-six patients with probable mild AD treated with a ChEI for 20 weeks were retrospectively divided into responders and non-responders. Patients were classified as responders if their Clinicians Interview Based Impression of Change (CIBIC - Plus) score was four or less and if they had an increase of at least two points on the MMSE. These criteria resulted in two subgroups comprising nine responders and seventeen non responders. Nine healthy elderly age-matched controls were also recruited as a comparison group. ChEI treatment was accompanied by significant modulation of task induced activation increases in both fMRI tasks in AD responders. The effect of ChEI response was in effect a restoration of regional brain function in the same areas used by elderly controls when performing these tasks. In non-responders decrements in task related activation were observed and over time activation patterns appeared less like the elderly controls. Screening semantic fluency scores correlated negatively with activation increases at retest. In the paper, a tentative explanation is offered of why subgroups of patients with a similar clinical diagnosis and level of clinical severity show a different physiological response to ChE inhibition.
Keywords: Alzheimer's disease, response, treatment, fMRI, ChEI, dementia
Current Alzheimer Research
Title: Responders to ChEI Treatment of Alzheimers Disease Show Restitution of Normal Regional Cortical Activation
Volume: 6 Issue: 2
Author(s): Annalena Venneri, William J. McGeown and Michael F. Shanks
Affiliation:
Keywords: Alzheimer's disease, response, treatment, fMRI, ChEI, dementia
Abstract: Clinical trials of cholinesterase inhibitor (ChEI) drugs, although generally reporting only minimal improvements in patients with Alzheimers disease (AD), indicate that a subgroup of patients may respond substantially to treatment. This study aimed to assess the clinically variable ChEI treatment effects in a group of patients with mild AD using a semantic association and an N-back light working memory activation paradigm. Twenty-six patients with probable mild AD treated with a ChEI for 20 weeks were retrospectively divided into responders and non-responders. Patients were classified as responders if their Clinicians Interview Based Impression of Change (CIBIC - Plus) score was four or less and if they had an increase of at least two points on the MMSE. These criteria resulted in two subgroups comprising nine responders and seventeen non responders. Nine healthy elderly age-matched controls were also recruited as a comparison group. ChEI treatment was accompanied by significant modulation of task induced activation increases in both fMRI tasks in AD responders. The effect of ChEI response was in effect a restoration of regional brain function in the same areas used by elderly controls when performing these tasks. In non-responders decrements in task related activation were observed and over time activation patterns appeared less like the elderly controls. Screening semantic fluency scores correlated negatively with activation increases at retest. In the paper, a tentative explanation is offered of why subgroups of patients with a similar clinical diagnosis and level of clinical severity show a different physiological response to ChE inhibition.
Export Options
About this article
Cite this article as:
Venneri Annalena, McGeown J. William and Shanks F. Michael, Responders to ChEI Treatment of Alzheimers Disease Show Restitution of Normal Regional Cortical Activation, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602933
DOI https://dx.doi.org/10.2174/156720509787602933 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Associate Editor:
Current Alzheimer Research The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis
Current Vascular Pharmacology Oxidative Stress in Post-Acute Ischemic Stroke Patients after Intensive Neurorehabilitation
Current Neurovascular Research Myopericarditis, as the First Sign of Rheumatoid Arthritis Relapse, Evaluated by Cardiac Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Neurophysiology of Sleep and Wakefulness: Basic Science and Clinical Implications
Current Neuropharmacology Telomerase Therapeutics for Degenerative Diseases
Current Molecular Medicine Antioxidant Status and Energy State of Erythrocytes in Alzheimer Dementia: Probing for Markers
CNS & Neurological Disorders - Drug Targets Patent Review on Network-based Elderly Healthcare System in the US
Recent Patents on Computer Science Sleep Related Disorders in the Elderly: An Overview
Current Respiratory Medicine Reviews An Aβ Sequestration Approach Using Non-Antibody Aβ Binding Agents
Current Alzheimer Research Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Towards the Full Automation of QC Release Tests for [18F]fluoride-labeled Radiotracers
Current Organic Chemistry A Simple High Efficiency Intra-Islet Transduction Protocol Using Lentiviral Vectors
Current Gene Therapy A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease
Current Alzheimer Research Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Editorial [Hot Topic: Auditory Processing Disorder (Guest Editors: Vasiliki Maria Iliadou)]
Current Pediatric Reviews AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design